Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ASND Ascendis Pharma A/S

Trading 05-20 11:50:15 EDT

121.14

+0.02

+0.02%

High122.13	Low120.66	Vol75.34K
Open121.02	D1 Closing121.12	Amplitude1.21%
Mkt Cap6.95B	Tradable Cap6.89B	Total Shares57.35M
T/O9.14M	T/O Rate0.13%	Tradable Shares56.89M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ASND","market":"US","secType":"STK","nameCN":"Ascendis Pharma A/S","latestPrice":121.14,"timestamp":1716220173323,"preClose":121.12,"halted":0,"volume":75336,"delay":0,"floatShares":56893693,"shares":57345189,"eps":-9.57998,"marketStatus":"Trading","change":0.02,"latestTime":"05-20 11:50:15 EDT","open":121.02,"high":122.13,"low":120.66,"amount":9138558.89736,"amplitude":0.012137,"askPrice":121.47,"askSize":3,"bidPrice":121.09,"bidSize":160,"shortable":3,"etf":0,"ttmEps":-9.57998,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Market Trading","tradingStatus":3,"beginTime":1716235200000},"marketStatusCode":2,"adr":1,"adrRate":1,"listingDate":1422421200000,"exchange":"NASDAQ","adjPreClose":121.12,"preHourTrading":{"tag":"盘前","latestPrice":119.99,"preClose":121.12,"latestTime":"04:08 EDT","volume":10,"amount":1199.8999999999999,"timestamp":1716192502906},"postHourTrading":{"tag":"盘后","latestPrice":121.12,"preClose":121.12,"latestTime":"18:34 EDT","volume":49164,"amount":5954761.88,"timestamp":1715985260445},"volumeRatio":0.276328},"requestUrl":"/m/hq/s/ASND/tweets","defaultTab":"tweets","newsList":[{"id":"2436987082","title":"Ascendis Pharma Expands Capital with Warrants and Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2436987082","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2436987082?lang=en_us&edition=fundamental","pubTime":"2024-05-17 05:27","pubTimestamp":1715894879,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S, a company focused on developing medical treatments for diseases, has announ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-expands-capital-with-warrants-and-shares?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-expands-capital-with-warrants-and-shares?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435546665","title":"FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months","url":"https://stock-news.laohu8.com/highlight/detail?id=2435546665","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2435546665?lang=en_us&edition=fundamental","pubTime":"2024-05-16 01:57","pubTimestamp":1715795828,"startTime":"0","endTime":"0","summary":"Hypoparathyroidism is an uncommon condition in which the body produces abnormally low levels of parathyroid hormone .The low production ofPTHin hypoparathyroidism leads to abnormally low calcium levels in the blood and an increase of phosphorus in the blood.The agency said the information Ascendis Pharmasubmitted in response to the FDA’s ongoing review of the New Drug Application  for TransCon PTH constituted amajoramendment to the NDA.Accordingly, the FDA has extended the PDUFA target action date by three months to August 14, 2024, from May 14 to provide time for afullsubmission review.“We have responded to all requests receivedto date from FDAand will work with the agency as they continue their review of our NDA,” said Jan Mikkelsen, Ascendis Pharma’s President and CEO.AlsoRead:Ascendis Pharma’s Growth Hormone Deficiency Candidate Outperforms in Phase 3 Trial.This article FDA Pushes Review Date For Ascendis Pharma's Hormone Disorder Candidate By Three Months originally appeared on Be","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/_FnI.dxg5iNvnES2gC.csQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/bbff94b157f68f51f50e2bd117463da3","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/_FnI.dxg5iNvnES2gC.csQ--~B/aD01NTM7dz05ODM7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Benzinga/bbff94b157f68f51f50e2bd117463da3"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-pushes-review-date-ascendis-175708091.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435657362","title":"FDA Delays Decision on Ascendis' (ASND) Hormone Therapy Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2435657362","media":"Zacks","top":-1,"share":"https://ttm.financial/m/news/2435657362?lang=en_us&edition=fundamental","pubTime":"2024-05-15 22:44","pubTimestamp":1715784240,"startTime":"0","endTime":"0","summary":"Shares of Ascendis Pharma ASND lost more than 5% on Tuesday after management announced that the FDA extended the review period for its regulatory filing for a hormone replacement therapy by an additional three months. A final decision is now expected by Aug 14, 2024.This filing is a resubmission that was accepted by the FDA last year in December. Little over a year ago, the agency had issued a complete response letter  to the company’s initial filing, citing a manufacturing issue and questioning the variability of delivered doses of the treatment for dose variability of the therapy. The FDA did not raise any concerns about clinical data in the CRL.Currently, Ascendis has only one marketed drug in its portfolio, Skytrofa , which was approved by the FDA in 2021 for treating growth hormone deficiency in children aged one year and older. A potential approval for TransCon could help the company diversify and expand its top line, which is currently solely dependent on one m","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/B7EfA6ERTo_QO90H15uyXw--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/9c1d11cd27737fac4805145de6e5eee0"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/fda-delays-decision-ascendis-asnd-144400606.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435063908","title":"Ascendis Pharma (ASND) Gets a Hold from Oppenheimer","url":"https://stock-news.laohu8.com/highlight/detail?id=2435063908","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435063908?lang=en_us&edition=fundamental","pubTime":"2024-05-15 19:46","pubTimestamp":1715773594,"startTime":"0","endTime":"0","summary":"Oppenheimer analyst Leland Gershell maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today. The company’s shares closed yesterd...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-gets-a-hold-from-oppenheimer-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-gets-a-hold-from-oppenheimer-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435639857","title":"Analysts Are Bullish on These Healthcare Stocks: Ascendis Pharma (ASND), Sanara MedTech (SMTI)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435639857","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435639857?lang=en_us&edition=fundamental","pubTime":"2024-05-15 19:20","pubTimestamp":1715772009,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Ascendis Pharma (ASND – Research Report), Sanara Med...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-ascendis-pharma-asnd-sanara-medtech-smti?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-ascendis-pharma-asnd-sanara-medtech-smti?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435639861","title":"Ascendis Pharma (ASND) Receives a Hold from TD Cowen","url":"https://stock-news.laohu8.com/highlight/detail?id=2435639861","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435639861?lang=en_us&edition=fundamental","pubTime":"2024-05-15 19:15","pubTimestamp":1715771754,"startTime":"0","endTime":"0","summary":"TD Cowen analyst Yaron Werber maintained a Hold rating on Ascendis Pharma (ASND – Research Report) today and set a price target of $156.00. The com...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-hold-from-td-cowen-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/ascendis-pharma-asnd-receives-a-hold-from-td-cowen-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435579607","title":"Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Annexon Biosciences (ANNX) and Ascendis Pharma (ASND)","url":"https://stock-news.laohu8.com/highlight/detail?id=2435579607","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435579607?lang=en_us&edition=fundamental","pubTime":"2024-05-15 09:10","pubTimestamp":1715735423,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alcon (ALC – Research Report), Annexon Biosciences (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alcon-alc-annexon-biosciences-annx-and-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-alcon-alc-annexon-biosciences-annx-and-ascendis-pharma-asnd?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435528206","title":"US Equity Markets Close Higher Tuesday as Producer Prices Rise","url":"https://stock-news.laohu8.com/highlight/detail?id=2435528206","media":"MT Newswires","top":-1,"share":"https://ttm.financial/m/news/2435528206?lang=en_us&edition=fundamental","pubTime":"2024-05-15 04:07","pubTimestamp":1715717235,"startTime":"0","endTime":"0","summary":"US equity markets ended higher Tuesday as the producer price index increased more than expected.* The US Producer Price Index rose 0.5% in April following a downwardly revised 0.1% decrease in March, above the 0.3% gain expected in a survey compiled by Bloomberg. Core prices, which exclude food and energy, also rose 0.5% after a 0.1% decrease in the previous month.* The National Federation of Independent Business' monthly sentiment index rebounded to 89.7 in April from 88.5 in March, with gains in seven of the 10 components, particularly for sales expectations. Concerns about inflation, rising costs and economic uncertainty still weigh on small businesses.* June West Texas Intermediate crude oil closed down $1.10 to $78.06 per barrel, while July Brent crude, the global benchmark, was last seen down $0.95 to $82.41.* AMC Entertainment  shares jumped 33% after the company raised $250 million from its at-the-market offering of 72.5 million shares at an average price of $3.45 each.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-equity-markets-close-higher-200715488.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2435599528","title":"FDA Delays Ascendis Pharma’s Drug Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2435599528","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2435599528?lang=en_us&edition=fundamental","pubTime":"2024-05-15 03:58","pubTimestamp":1715716711,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S has announced a three-month delay by the FDA for the review of their New Dru...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/fda-delays-ascendis-pharmas-drug-review?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/fda-delays-ascendis-pharmas-drug-review?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2435954271","title":"Ascendis Pharma says FDA has delayed TransCon PTH review","url":"https://stock-news.laohu8.com/highlight/detail?id=2435954271","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2435954271?lang=en_us&edition=fundamental","pubTime":"2024-05-15 03:08","pubTimestamp":1715713688,"startTime":"0","endTime":"0","summary":"Ascendis Pharma (ASND) announced Tuesday that the U.S. Food and Drug Administration (FDA) has pushed back the timeline to complete its review of the company's investigational hypoparathyroidism therap","market":"sg","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1286971245/image_1286971245.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4106056-ascendis-stock-falls-fda-delays-transcon-pth-review","is_publish_highlight":false,"gpt_icon":0},{"id":"2435912542","title":"Ascendis Pharma Says FDA Extending Review Period for NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2435912542","media":"Dow Jones","top":-1,"share":"https://ttm.financial/m/news/2435912542?lang=en_us&edition=fundamental","pubTime":"2024-05-15 02:56","pubTimestamp":1715712960,"startTime":"0","endTime":"0","summary":"Ascendis Pharma said regulators had pushed back the target action date for reviewing its hypoparathyroidism treatment after the company submitted additional information.The Danish biopharmaceutical company said Tuesday that the U.S. Food and Drug Administration had informed the company that its new target date was Aug. 14, compared with its previous date of May 14.The FDA can extend review periods for NDAs if there are major amendments to the applications.Ascendis Chief Executive Jan Mikkelsen said the company had responded to all requests received from FDA at this point and is committed to bringing the treatment to patients.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"gpt_icon":0},{"id":"2435544082","title":"FDA extends review of Ascendis Pharma's hormone disorder therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2435544082","media":"Reuters","top":-1,"share":"https://ttm.financial/m/news/2435544082?lang=en_us&edition=fundamental","pubTime":"2024-05-15 02:38","pubTimestamp":1715711883,"startTime":"0","endTime":"0","summary":"May 14  -    The U.S. Food & Drug Administration has extended its review of Ascendis Pharma's    therapy to treat adult patients with a hormone disorder, the company said on Tuesday.   The FDA is now set to make its decision known by Aug. 14, compared to its previous action date set for May 14. ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"gpt_icon":0},{"id":"2433930427","title":"Analysts Have Conflicting Sentiments on These Healthcare Companies: Ascendis Pharma (ASND), Owens & Minor (OMI) and Illumina (ILMN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2433930427","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2433930427?lang=en_us&edition=fundamental","pubTime":"2024-05-08 12:20","pubTimestamp":1715142010,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Ascendis Pharma (ASND – Research Report), Owens & Minor (OMI – Re...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ascendis-pharma-asnd-owens-minor-omi-and-illumina-ilmn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-have-conflicting-sentiments-on-these-healthcare-companies-ascendis-pharma-asnd-owens-minor-omi-and-illumina-ilmn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2433747240","title":"Ascendis Pharma A/S (NASDAQ:ASND) Q1 2024 Earnings Call Transcript","url":"https://stock-news.laohu8.com/highlight/detail?id=2433747240","media":"Insider Monkey","top":-1,"share":"https://ttm.financial/m/news/2433747240?lang=en_us&edition=fundamental","pubTime":"2024-05-06 21:59","pubTimestamp":1715003968,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter .These statements are based on information that is available to us today. Actual results may differ -- could differ materially from those in our forward-looking statements, and you should not place undue reliance on these statements. We assume no obligation to update these statements as circumstances change, except as required by law. For additional information concerning the factors that can cause actual results to differ materially, please see our forward-looking statements section in today's press release and the risk factors section of our most recent annual report on Form 20-F filed with the SEC on February 7, 2024. TransCon Growth Hormone, or TransCon hGH, is approved by the -- is approved in the US by FDA and the EU has received MAA authorization from the European Commission for the treatment of pediatric growth hor","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/yOou9HhfLFl6oabErUhkNw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8e14be836d38ca491349fe0482abf90f","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/yOou9HhfLFl6oabErUhkNw--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8e14be836d38ca491349fe0482abf90f"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascendis-pharma-nasdaq-asnd-q1-135928667.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432437911","title":"Ascendis Pharma First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2432437911","media":"Simply Wall St.","top":-1,"share":"https://ttm.financial/m/news/2432437911?lang=en_us&edition=fundamental","pubTime":"2024-05-04 21:07","pubTimestamp":1714828075,"startTime":"0","endTime":"0","summary":"NasdaqGS:ASND Earnings and Revenue Growth May 4th 2024. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 18%. Earnings per share  missed analyst estimates by 61%.Looking ahead, revenue is forecast to grow 37% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.The company's share price is broadly unchanged from a week ago.Before we wrap up, we've discovered 2 warning signs for Ascendis Pharma (1 shouldn't be ignored!","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/5Vpve0Pc2F3m_L3fs2p_dQ--~B/aD02MzY7dz05NDU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/78a8c60a6283aea0450523395306d38c"],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ascendis-pharma-first-quarter-2024-130755803.html","is_publish_highlight":false,"gpt_icon":0},{"id":"2432250968","title":"Ascendis Pharma A/S Boasts Strong Q1 Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2432250968","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432250968?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:58","pubTimestamp":1714687138,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S has reported a substantial first quarter growth in 2024, with SKYTROFA reven...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-a-s-boasts-strong-q1-growth?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-a-s-boasts-strong-q1-growth?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432968233","title":"Ascendis Pharma Posts Q1 Revenue Growth Amid Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2432968233","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432968233?lang=en_us&edition=fundamental","pubTime":"2024-05-03 05:57","pubTimestamp":1714687046,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S, a biopharmaceutical company, reported increased revenue of EUR 95,894,000 f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-posts-q1-revenue-growth-amid-losses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-posts-q1-revenue-growth-amid-losses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432951791","title":"Ascendis Pharma Outlines AGM Agenda and Proposals","url":"https://stock-news.laohu8.com/highlight/detail?id=2432951791","media":"TIPRANKS","top":-1,"share":"https://ttm.financial/m/news/2432951791?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:58","pubTimestamp":1714683527,"startTime":"0","endTime":"0","summary":"Ascendis Pharma A/S (ASND) has released an update. Ascendis Pharma A/S has announced its Annual General Meeting (AGM) scheduled for May 30th, 2024,...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-outlines-agm-agenda-and-proposals?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/ascendis-pharma-outlines-agm-agenda-and-proposals?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"gpt_icon":0},{"id":"2432959255","title":"Ascendis Pharma Q1 Sales €95.894M Beat €79.492M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2432959255","media":"Benzinga","top":-1,"share":"https://ttm.financial/m/news/2432959255?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:46","pubTimestamp":1714682763,"startTime":"0","endTime":"0","summary":"Ascendis Pharma Q1 Sales €95.894M Beat €79.492M Estimate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/05/38599562/ascendis-pharma-q1-sales-95-894m-beat-79-492m-estimate","is_publish_highlight":false,"gpt_icon":0},{"id":"2432593069","title":"Ascendis Pharma reports Q1 results","url":"https://stock-news.laohu8.com/highlight/detail?id=2432593069","media":"seekingalpha","top":-1,"share":"https://ttm.financial/m/news/2432593069?lang=en_us&edition=fundamental","pubTime":"2024-05-03 04:41","pubTimestamp":1714682481,"startTime":"0","endTime":"0","summary":"Ascendis Pharma press release : Q1 GAAP EPS of -2.30. Revenue of 95.9M . Cash, cash equivalents, and marketable securities totaling 320 million compared to 399 million as of December 31, 2023. Full year 2024 SKYTROFA revenue expected to be 320 million to 340 million .  Expect total operating expenses  of approximately 600 million for 2024. Expect to be operating cash flow breakeven on a quarterly basis by the end of 2024.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/news/4099201-ascendis-pharma-reports-q1-results","is_publish_highlight":false,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascendispharma.com","stockEarnings":[{"period":"1week","weight":-0.0925},{"period":"1month","weight":-0.1481},{"period":"3month","weight":-0.2255},{"period":"6month","weight":0.2751},{"period":"1year","weight":0.3553},{"period":"ytd","weight":-0.0383}],"compareEarnings":[{"period":"1week","weight":0.0165},{"period":"1month","weight":0.0577},{"period":"3month","weight":0.0599},{"period":"6month","weight":0.1745},{"period":"1year","weight":0.2629},{"period":"ytd","weight":0.1139}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia. In addition, it is developing TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/? for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.037189},{"month":2,"riseRate":0.5,"avgChangeRate":0.037735},{"month":3,"riseRate":0.5,"avgChangeRate":0.039038},{"month":4,"riseRate":0.3,"avgChangeRate":-0.046884},{"month":5,"riseRate":0.4,"avgChangeRate":-0.009488},{"month":6,"riseRate":0.555556,"avgChangeRate":0.01785},{"month":7,"riseRate":0.666667,"avgChangeRate":0.002177},{"month":8,"riseRate":0.666667,"avgChangeRate":0.086396},{"month":9,"riseRate":0.555556,"avgChangeRate":0.037325},{"month":10,"riseRate":0.444444,"avgChangeRate":0.006164},{"month":11,"riseRate":0.777778,"avgChangeRate":0.039978},{"month":12,"riseRate":0.444444,"avgChangeRate":0.049536}],"exchange":"NASDAQ","name":"Ascendis Pharma A/S","nameEN":"Ascendis Pharma A/S"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Ascendis Pharma A/S,ASND,Ascendis Pharma A/S股票,Ascendis Pharma A/S股票老虎,Ascendis Pharma A/S股票老虎国际,Ascendis Pharma A/S行情,Ascendis Pharma A/S股票行情,Ascendis Pharma A/S股价,Ascendis Pharma A/S股市,Ascendis Pharma A/S股票价格,Ascendis Pharma A/S股票交易,Ascendis Pharma A/S股票购买,Ascendis Pharma A/S股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Ascendis Pharma A/S(ASND),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Ascendis Pharma A/S(ASND) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}